Ironwood’s Linaclotide Set For China Filing On New Results
This article was originally published in PharmAsia News
Executive Summary
Ironwood's irritable bowel syndrome drug linaclotide has come out well from a Phase III trial conducted predominantly in China, setting the stage for a filing in this potentially large market where no prescription drug are currently available for its intended indication.